Trial intelligence / Profile preview

Melatonin for Initial Insomnia in Children With ADHD

NCT02333149Phase 3Withdrawn

Sponsor
University of Alberta
Start
Jan 2019
Primary completion
Nov 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, triple-blind trial in Insomnia comparing Melatonin with Placebo (2 arms). Primary endpoint: Sleep Onset Latency at 6 weeks. Planned start Jan 2019; status: withdrawn.

02

Drugs

melatonin
03

Conditions

Insomnia

Beyond the preview

Go deeper on NCT02333149.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02333149.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call